Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study.
The objective of the present study was to develop the mucoadhesive buccal film of valdecoxib for the treatment of oral sub mucous fibrosis, a localized buccal disease. Valdecoxib, a novel COX-2 inhibitor has been reported to be used in various osteopathic and rheumatoid conditions as oral therapy. The films were made out of chitosan and HPMC K4M as polymers. Sodium taurocholate was used as a permeation enhancer. All the formulations were examined for film thickness, swelling properties, drug content, weight variation, in vitro release studies, bioadhesive force, tensile strength, diffusion studies using pig mucosa and pharmacokinetic study in healthy male volunteers. Prepared films were thin, flexible, smooth and transparent. Bioadhesive force and tensile strength of the optimized formulation were found to be 75 +/- 4 kg m(-1) S(-2) and more than 2.5 kg/3 cm(2), respectively. The percent drug content was 98.5 +/- 1.3%. The in vitro drug release from the selected formulation showed that about 69.34% of the drug payload was released up to 6 hours. The drug permeation through the dialysis sac and pig buccal mucosa was found to be 62.70% and 54.39%, respectively. Pharmacokinetic studies of the buccal mucoadhesive film showed that the drug was released locally at the target site of action, and a very small amount might have absorbed systemically.
Averineni
Ranjith Kumar
RK
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka State, India. ranjith.kumar@manipal.edu
Sunderajan
Subramanian Ganesa
SG
Mutalik
Srinivas
S
Nayak
Usha
U
Shavi
Gopal
G
Armugam
Karthik
K
Meka
Sreenivasa Reddy
SR
Pandey
Sureshwar
S
Nayanabhirama
Udupa
U
D000268:Adhesiveness; D000278:Administration, Buccal; D000328:Adult; D000818:Animals; D048271:Chitosan / Q000008:administration & dosage / Q000737:chemistry*; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D004058:Diffusion; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D006801:Humans; D065347:Hypromellose Derivatives; D007555:Isoxazoles / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives / Q000737:chemistry; D009061:Mouth Mucosa / Q000378:metabolism*; D009914:Oral Submucous Fibrosis / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D013552:Swine; D013656:Taurocholic Acid / Q000737:chemistry; D013718:Tensile Strength; D000096926:Benzenesulfonamides
D048271:Chitosan; D016861:Cyclooxygenase Inhibitors; D004337:Drug Carriers; D065347:Hypromellose Derivatives; D007555:Isoxazoles; D008747:Methylcellulose; D013449:Sulfonamides; D013656:Taurocholic Acid; C406224:valdecoxib; D000096926:Benzenesulfonamides